The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Guidelines | Esophageal/Esophagogastric Junction Cancers Guideline Updates 2026
Esophageal/Esophagogastric Junction Cancers Guideline Updates 2026
Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
IVF Beats IUI for Early Live Births in Unexplained Infertility
4
Early-Onset Cancers Often Found Late as Screening Gaps Persist
5